ongoing trials trial from www.clinicaltrials.gov Study With Phage for CF Subjects With Pseudomonas Lung Infection Year: 2025 Date: Author: Study design (if review, criteria of inclusion for studies) Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT Participants ADULT, OLDER_ADULT Interventions BIOLOGICAL: BX004|OTHER: Placebo Outcome measures Change in sputum Pseudomonas aeruginosa (PsA) burden at 8 weeks (EOT), Change from baseline in PsA colony-forming units (CFU) per g of sputum, 8 weeks Related topics Antibiotic treatment for stenotrophomonas maltophilia in people with cystic fibrosis Antibiotic treatment of early pseudomonas aeruginosa Antibiotics for pulmonary exacerbations Inhaled antibiotics in cystic fibrosis MRSA eradication in CF Prophylactic use of oral antistaphylococcal antibiotic Scheduled antibiotics every 3-4 months / symptom-based treatment